President Donald Trump announced voluntary drug-pricing agreements with nine additional pharmaceutical manufacturers on August 31, 2026, bringing total participating drugmakers to 26 and covering roughly 89 percent of the branded pharmaceutical market. According to the White House, the agreements are part of the Most Favored Nation initiative designed to align United States prescription drug costs with lower prices paid in other developed nations.
Expansion of the Most Favored Nation Initiative
The latest additions to the administration’s pricing pacts include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, according to official White House announcements. Kennedy Jr. stated in the Oval Office that President Trump emphasized that officials’ jobs depended on achieving lower healthcare costs for consumers. “For decades, Americans paid the highest drug prices anywhere in the world, by far,” President Trump said during the announcement.
The voluntary agreements require participating manufacturers to provide Most Favored Nation pricing to state Medicaid programs. According to the administration, the companies also committed to ensuring that future innovative medicines are offered to Americans at prices comparable to those available in other developed nations. Teva USA President Chris Fox noted in a press release that his company appreciates the opportunity to work with the administration to expand access and affordability while continuing investments in scientific innovation and domestic manufacturing capabilities.
Targeted Medications and Price Reductions
While the administration did not immediately release a comprehensive list of every affected medicine, official releases indicate the pacts cover products addressing chronic and high-cost conditions such as hemophilia, Parkinson’s disease, glaucoma, macular degeneration, and certain cancers.
These voluntary pacts build on previous agreements secured over the prior 11 months, following letters sent to drug manufacturers in 2025. President Trump stated on August 31, 2026, that he expects remaining brand-name drug manufacturers to sign because they “have no choice,” adding that the negotiations are tied to avoiding future tariffs.
Policy Contrasts and Industry Response
The Trump administration’s voluntary framework differs structurally from the Medicare drug-price negotiation program established under former President Joe Biden’s Inflation Reduction Act, which authorizes Medicare to negotiate prices directly for selected high-cost medications used by seniors. Administration officials characterize their approach as a direct counter to global pricing disparities, arguing that foreign governments benefit from lower rates while pharmaceutical companies recover development costs through higher U.S. prices.
Patient advocacy groups have raised questions regarding the long-term impact of these voluntary terms. Merith Basey, CEO of Patients for Affordable Drugs, stated that the newly announced deals focus primarily on Medicaid programs where steep discounts already exist, and noted that states retain the choice of whether to participate. “Lasting relief requires transparent, enforceable measures that hold big drug companies accountable,” Basey said, calling for systemic reforms rather than short-term voluntary agreements whose detailed terms remain undisclosed to the public.
Related reading